Pirfenidone-d5

Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].

Product Specifications

CAS Number

[1020719-62-3]

Product Name Alternative

AMR69-d5

UNSPSC

12352005

Hazard Statement

H302

Target

CCR; TGF-beta/Smad

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Purity

98.88

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C=CC(C)=CN1C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H]

Molecular Formula

C12H6D5NO

Molecular Weight

190.25

Precautions

P264-P270-P330-P501

References & Citations

[1]Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354 (2) :542-7.|[2]Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446 (1-3) :177-85.|[3]Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16.